our Premium Content: News alerts, weekly reports and conference planners

GENE:

MCM4 (Minichromosome Maintenance Complex Component 4)

News alerts, weekly reports and conference planners

18d

Proteomics Profiling Identifies MCM4 as a Prognostic Biomarker for Postoperative Metastasis in Solid Pseudopapillary Neoplasms of the Pancreas. (PubMed, Mod Pathol)

Time-dependent ROC analyses demonstrated that MCM4 positivity achieved AUCs of 0.817 (95% CI: 0.763-0.864) at 3 years and 0.777 (95% CI: 0.720-0.828) at 5 years for postoperative metastasis assessment. Taken together, these findings identify MCM4 positivity as an independent prognostic biomarker for postoperative metastasis risk assessment in SPN.

18 days ago

Journal

MCM4 (Minichromosome Maintenance Complex Component 4)

23d

Integrated omics and machine learning uncover the molecular basis of environmental toxicant 6PPD-Qinduced non-obstructive azoospermia. (PubMed, Ecotoxicol Environ Saf)

This study provides a mechanistic hypothesis for 6PPD-Q-induced testicular dysfunction and offers candidate targets for future experimental validation in environmental reproductive toxicology.

23 days ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • AR (Androgen receptor) • AURKA (Aurora kinase A) • CASP8 (Caspase 8) • MCM4 (Minichromosome Maintenance Complex Component 4)

24d

Integrative Bioinformatics and Experimental Validation Establish CCNB1 as a Potential Biomarker for Diagnosis and Prognosis in Colorectal Cancer. (PubMed, Curr Issues Mol Biol)

In vitro, CCNB1 knockdown triggered cell cycle arrest, thereby suppressing the proliferation of colorectal cancer cells. This study validated CCNB1 as a dual-purpose biomarker for CRC diagnosis and favorable prognosis, highlighting its potential utility in clinical management.

24 days ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • CDCA3 (Cell Division Cycle Associated 3) • CCNA2 (Cyclin A2) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • CDC20 (Cell Division Cycle 20) • KIF11 (Kinesin Family Member 11) • MCM4 (Minichromosome Maintenance Complex Component 4) • CCNB1 (Cyclin B1) • CDK3 (Cyclin Dependent Kinase 3) • CEP55 (Centrosomal Protein 55) • CKS2 (CDC28 Protein Kinase Regulatory Subunit 2) • CRYAB (Crystallin Alpha B) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • MMP3 (Matrix metallopeptidase 3) • TPM2 (Tropomyosin 2) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)

3ms

Integrative Multi-Omics and Functional Characterization Reveal MCM4 as a Key Oncogenic Regulator in Hepatocellular Carcinoma. (PubMed, Onco Targets Ther)

Our study establishes MCM4 as a key regulator of HCC progression and a potential prognostic biomarker. These findings suggest that MCM4 may serve as a potential target and underscore integrative and spatial transcriptomic approaches in cancer biomarker discovery.

3 months ago

Journal

MCM4 (Minichromosome Maintenance Complex Component 4)

3ms

Integrated Genomic and Transcriptomic Profiling of Isolated Trisomies in AML Reveals Cell Cycle Dysregulation and Therapeutic Vulnerabilities. (PubMed, J Cell Mol Med)

Drug sensitivity profiling revealed subgroup-specific vulnerabilities: IT-8 to DNA damage checkpoint inhibitors, IT-21 to PLK/mTOR inhibitors and IT-13+22 to BRAF/EGFR-targeted agents. These findings highlight AML-IT heterogeneity and therapeutic potential.

3 months ago

Journal

BRAF (B-raf proto-oncogene) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CALR (Calreticulin) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • MCM4 (Minichromosome Maintenance Complex Component 4) • CDC25A (Cell Division Cycle 25A) • CDC7 (Cell Division Cycle 7) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1)

4ms

Plasma exosomal lncRNA-related signatures define molecular subtypes and predict survival and treatment response in hepatocellular carcinoma. (PubMed, Front Immunol)

Risk model analysis predicted differential treatment responses: low-risk patients exhibited superior anti-PD-1 immunotherapy responses, whereas high-risk patients showed increased sensitivity to DNA-damaging agents (e.g., the Wee1 inhibitor MK-1775) and sorafenib. Plasma exosomal lncRNAs enable robust molecular subtyping, accurate prognostic stratification, and treatment response prediction in HCC. The ERG-centric classification system and validated 6-gene risk model provide clinically actionable tools for precision oncology.

4 months ago

Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TTN (Titin) • TGFB1 (Transforming Growth Factor Beta 1) • ADH1C (Alcohol Dehydrogenase 1C (Class I), Gamma Polypeptide) • MCM4 (Minichromosome Maintenance Complex Component 4) • NDRG1 (N-Myc Downstream Regulated 1) • RECQL4( RecQ Like Helicase 4) • KIF20A (Kinesin Family Member 20A)

PD-L1 expression • TP53 mutation

sorafenib • adavosertib (AZD1775)

5ms

Comprehensive analysis reveals MCM4 as a biomarker for guiding therapies and immunomodulatory role in skin cutaneous melanoma. (PubMed, J Cancer)

Functional experiments confirmed the oncogenesis effects of MCM4 in SKCM cells. MCM4 is a potential prognostic biomarker and predictor of immunotherapy response in SKCM patients.

5 months ago

Journal • IO biomarker

MCM4 (Minichromosome Maintenance Complex Component 4)

6ms

Proliferative proteome induced by HPV 16E6 and NFX1-123 partnership in longitudinal keratinocyte cultures. (PubMed, J Virol)

This study leverages proteomics to reinforce the synergistic actions of HPV16E6 and NFX1-123 and identifies cellular pathways impacted by this protein partnership over time. These findings encourage further investigation of NFX1-123 as a potential therapeutic target of HPV 16-positive tissues.

6 months ago

Licensing / partnership • Journal

MCM4 (Minichromosome Maintenance Complex Component 4) • MCM2 (Minichromosome maintenance complex component 2)

7ms

CDK inhibitors promote neuroblastoma cell differentiation and increase sensitivity to retinoic acid-a promising combination strategy for therapeutic intervention. (PubMed, Cell Death Discov)

This study investigated three CDKis (abemaciclib, fadraciclib, and dinaciclib) alone or combined with retinoic acid (RA) to assess the effects on morphology, growth, gene expression, and the induction of immunogenic cell death in NB cell lines with (LAN-1 and CHLA-90) and without (CHLA-172) MYCN amplification. CDKi treatments promote NB differentiation via ER stress, with cytotoxicity enhanced by RA co-treatment. This may increase NB immunogenicity and support immunotherapy eligibility.

7 months ago

Journal • IO biomarker

CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CDK4 (Cyclin-dependent kinase 4) • CALR (Calreticulin) • CCNE2 (Cyclin E2) • MCM4 (Minichromosome Maintenance Complex Component 4) • MYBL2 (MYB Proto-Oncogene Like 2) • ROBO2 (Roundabout Guidance Receptor 2)

CDKN2A deletion

Verzenio (abemaciclib) • fadraciclib (CYC065) • dinaciclib (MK-7965)

8ms

Exploring the pathogenesis of extranodal natural killer/T cell lymphoma complicated With EBV via microarray data analysis. (PubMed, Leuk Res)

In this study we identified the common DEGs of ENKL and EBV infections, found 14 hub DEGs that may mediate between them. Hope this study could provide new insights for further study of the molecular mechanism between EBV infection and ENKL.

8 months ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • TYMS (Thymidylate Synthetase) • AURKB (Aurora Kinase B) • CCNA2 (Cyclin A2) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • CDC20 (Cell Division Cycle 20) • KIF11 (Kinesin Family Member 11) • MCM4 (Minichromosome Maintenance Complex Component 4) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • CCNB1 (Cyclin B1) • FEN1 (Flap Structure-Specific Endonuclease 1) • MCM3 (Minichromosome maintenance complex component 3) • MCM6 (Minichromosome Maintenance Complex Component 6)

8ms

MCM4 as Potential Metastatic Biomarker in Lung Adenocarcinoma. (PubMed, Diagnostics (Basel))

MCM4 is a novel potential biomarker for LUAD metastasis and prognosis. Its consistent upregulation, association with metastatic markers, and clinical significance suggest it may serve as a candidate target for diagnostic use or therapeutic intervention in advanced LUAD.

8 months ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • AURKA (Aurora kinase A) • MELK (Maternal Embryonic Leucine Zipper Kinase) • CCNB2 (Cyclin B2) • MCM4 (Minichromosome Maintenance Complex Component 4) • KIF20A (Kinesin Family Member 20A)

8ms

Topoisomerase I Inhibition in ETV4-overexpressed Non-Small Cell Lung Cancer Promotes Replication and Transcription Mediated R-Loop Accumulation and DNA Damage. (PubMed, Adv Sci (Weinh))

Due to its binding at the origin-promoter locus like the MCM4 gene, ETV4 overexpression increases R-loop formation, DNA damage, and cell death under external replication stress induced by topoisomerase I (TOP1) inhibitor. These findings highlight the dual role of ETV4 in replication and transcription and suggest that targeting TOP1 could be a synthetic-lethal approach in ETV4-overexpressed lung cancer.

8 months ago

Journal

MCM10 (Minichromosome Maintenance 10 Replication Initiation Factor) • MCM4 (Minichromosome Maintenance Complex Component 4) • ETV4 (ETS Variant Transcription Factor 4) • MCM2 (Minichromosome maintenance complex component 2) • MCM5 (Minichromosome Maintenance Complex Component 5) • ORC1 (Origin Recognition Complex Subunit 1)